Pushing to make critically needed pharmaceuticals more affordable, India is restricting trade margins on the selling prices of dozens of cancer drugs.
The move announced in February 2019 by the National Pharmaceutical Pricing Authority (NPPA) caps trade margins of 42 cancer drugs at 30%. It will force manufacturers to reduce retail prices on the drugs by as much as 85%.
The price controls, which came into effect March 8, apply to 72 formulations and 355 brands. The prices of 57 other cancer drugs are already capped